

Brent A Hanks

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3737783/publications.pdf>

Version: 2024-02-01

57
papers

2,462
citations

331670

21
h-index

254184

43
g-index

57
all docs

57
docs citations

57
times ranked

4115
citing authors

#	ARTICLE	IF	CITATIONS
1	Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy. <i>Journal of Clinical Oncology</i> , 2019, 37, 693-702.	1.6	274
2	Tumor Mutational Burden as a Predictor of Immunotherapy Response: Is More Always Better?. <i>Clinical Cancer Research</i> , 2021, 27, 1236-1241.	7.0	222
3	Paracrine Wnt5a- β -Catenin Signaling Triggers a Metabolic Program that Drives Dendritic Cell Tolerization. <i>Immunity</i> , 2018, 48, 147-160.e7.	14.3	185
4	Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy. , 2017, 5, 44.		181
5	Melanoma-Derived Wnt5a Promotes Local Dendritic-Cell Expression of IDO and Immunotolerance: Opportunities for Pharmacologic Enhancement of Immunotherapy. <i>Cancer Immunology Research</i> , 2015, 3, 1082-1095.	3.4	147
6	A tumor-intrinsic PD-L1/NLRP3 inflammasome signaling pathway drives resistance to anti- α -PD-1 immunotherapy. <i>Journal of Clinical Investigation</i> , 2020, 130, 2570-2586.	8.2	134
7	Type III TGF- β 2 receptor downregulation generates an immunotolerant tumor microenvironment. <i>Journal of Clinical Investigation</i> , 2013, 123, 3925-3940.	8.2	94
8	Genetic risk analysis of a patient with fulminant autoimmune type 1 diabetes mellitus secondary to combination ipilimumab and nivolumab immunotherapy. , 2016, 4, 89.		81
9	Stromal Fibroblasts Mediate Anti- α -PD-1 Resistance via MMP-9 and Dictate TGF β 2 Inhibitor Sequencing in Melanoma. <i>Cancer Immunology Research</i> , 2018, 6, 1459-1471.	3.4	81
10	Re-engineered CD40 receptor enables potent pharmacological activation of dendritic-cell cancer vaccines in vivo. <i>Nature Medicine</i> , 2005, 11, 130-137.	30.7	79
11	Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma. , 2019, 7, 80.		65
12	Safety and Efficacy of Radiation Therapy in Advanced Melanoma Patients Treated With Ipilimumab. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 72-77.	0.8	64
13	Role of Conserved Residues within the Carboxy Phosphate Domain of Carbamoyl Phosphate Synthetase β . <i>Biochemistry</i> , 1996, 35, 14352-14361.	2.5	61
14	Enhanced Activation of Human Dendritic Cells by Inducible CD40 and Toll-like Receptor-4 Ligation. <i>Cancer Research</i> , 2007, 67, 10528-10537.	0.9	61
15	Role of Tumor-Mediated Dendritic Cell Tolerization in Immune Evasion. <i>Frontiers in Immunology</i> , 2019, 10, 2876.	4.8	60
16	Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma. , 2021, 9, e002478.		59
17	Flt3 ligand augments immune responses to anti-DEC-205-NY-ESO-1 vaccine through expansion of dendritic cell subsets. <i>Nature Cancer</i> , 2020, 1, 1204-1217.	13.2	58
18	Rapid complete response of metastatic melanoma in a patient undergoing ipilimumab immunotherapy in the setting of active ulcerative colitis. , 2015, 3, 19.		54

#	ARTICLE	IF	CITATIONS
19	The State of Melanoma: Emergent Challenges and Opportunities. <i>Clinical Cancer Research</i> , 2021, 27, 2678-2697.	7.0	53
20	Inhibition of estrogen signaling in myeloid cells increases tumor immunity in melanoma. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	40
21	Structural Fluctuations of a Cryptophane Host: A Molecular Dynamics Simulation. <i>Journal of the American Chemical Society</i> , 1996, 118, 3237-3246.	13.7	39
22	Isolated recto-sigmoid colitis: a new imaging pattern of ipilimumab-associated colitis. <i>Abdominal Radiology</i> , 2016, 41, 207-214.	2.1	36
23	Comparison of the Functional Differences for the Homologous Residues within the Carboxy Phosphate and Carbamate Domains of Carbamoyl Phosphate Synthetase. <i>Biochemistry</i> , 1996, 35, 14362-14369.	2.5	35
24	Updates in adjuvant systemic therapy for melanoma. <i>Journal of Surgical Oncology</i> , 2019, 119, 222-231.	1.7	35
25	Pharmacological Wnt ligand inhibition overcomes key tumor-mediated resistance pathways to anti-PD-1 immunotherapy. <i>Cell Reports</i> , 2021, 35, 109071.	6.4	35
26	Combinatorial TGF- β 2 signaling blockade and anti-CTLA-4 antibody immunotherapy in a murine BRAF ^{V600E} -PTEN ^{-/-} transgenic model of melanoma. <i>Journal of Clinical Oncology</i> , 2014, 32, 3011-3011.	1.6	25
27	SITC cancer immunotherapy resource document: a compass in the land of biomarker discovery. , 2020, 8, e000705.		20
28	APOBEC Mutagenesis Inhibits Breast Cancer Growth through Induction of T cell-Mediated Antitumor Immune Responses. <i>Cancer Immunology Research</i> , 2022, 10, 70-86.	3.4	20
29	Improved Time to Progression for Transarterial Chemoembolization Compared With Transarterial Embolization for Patients With Unresectable Hepatocellular Carcinoma. <i>Clinical Colorectal Cancer</i> , 2012, 11, 185-190.	2.3	15
30	Higher BMI, But Not Sarcopenia, Is Associated With Pembrolizumab-related Toxicity in Patients With Advanced Melanoma. <i>Anticancer Research</i> , 2020, 40, 5245-5254.	1.1	14
31	The efficacy and tolerability of transarterial chemo-embolization (TACE) compared with transarterial embolization (TAE) for patients with unresectable hepatocellular carcinoma (HCC). <i>Journal of Clinical Oncology</i> , 2008, 26, 4595-4595.	1.6	14
32	A Phase II Randomized Study of CDX-1401, a Dendritic Cell Targeting NY-ESO-1 Vaccine, in Patients with Malignant Melanoma Pre-Treated with Recombinant CDX-301, a Recombinant Human Flt3 Ligand. <i>Journal of Clinical Oncology</i> , 2016, 34, 9589-9589.	1.6	14
33	Immunotherapy Following Regional Chemotherapy Treatment of Advanced Extremity Melanoma. <i>Annals of Surgical Oncology</i> , 2014, 21, 2525-2531.	1.5	13
34	Early Carcinogenesis Involves the Establishment of Immune Privilege via Intrinsic and Extrinsic Regulation of Indoleamine 2,3-dioxygenase-1: Translational Implications in Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2014, 5, 438.	4.8	12
35	Retrospective analysis of safety and efficacy of anti-PD-1 therapy and radiation therapy in advanced melanoma: A bi-institutional study. <i>Radiotherapy and Oncology</i> , 2019, 138, 114-120.	0.6	11
36	Role of dendritic cell metabolic reprogramming in tumor immune evasion. <i>International Immunology</i> , 2020, 32, 485-491.	4.0	11

#	ARTICLE	IF	CITATIONS
37	Overcoming Immunotherapy Resistance by Targeting the Tumor-Intrinsic NLRP3-HSP70 Signaling Axis. <i>Cancers</i> , 2021, 13, 4753.	3.7	9
38	Template-based docking of a prolactin receptor proline-rich motif octapeptide to FKBP12: Implications for cytokine receptor signaling. <i>Protein Science</i> , 1997, 6, 999-1008.	7.6	6
39	Dissecting the immune landscape of tumor draining lymph nodes in melanoma with high-plex spatially resolved protein detection. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 475-483.	4.2	6
40	The "Inside" Story on Tumor-Expressed PD-L1. <i>Cancer Research</i> , 2022, 82, 2069-2071.	0.9	6
41	Pilot trial of an Indoleamine 2,3-dioxygenase-1 (IDO1) inhibitor plus a multipeptide melanoma vaccine in patients with advanced melanoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 3033-3033.	1.6	5
42	The utility of initial staging PET-CT as a baseline scan for surveillance imaging in stage II and III melanoma. <i>Surgical Oncology</i> , 2020, 35, 533-539.	1.6	4
43	Clinical Trials with Biologic Primary Endpoints in Immuno-oncology: Concepts and Usage. <i>Clinical Cancer Research</i> , 2022, 28, 13-22.	7.0	4
44	Paracrine wnt- β -catenin signaling inhibition as a strategy to enhance the efficacy of anti-PD-1 antibody (Ab) therapy in a transgenic model of melanoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 3053-3053.	1.6	4
45	Pharmacological inhibition of TGF β 2 as a strategy to augment the antitumor immune response. <i>Current Opinion in Investigational Drugs</i> , 2010, 11, 1342-53.	2.3	4
46	Role of the Wnt- β -catenin signaling pathway in melanoma-mediated dendritic cell tolerization. , 2013, 1, P153.		3
47	Ipilimumab and Radiation in Patients with High-risk Resected or Regionally Advanced Melanoma. <i>Clinical Cancer Research</i> , 2021, 27, 1287-1295.	7.0	2
48	Targeting the Wnt5a- β -catenin pathway in the melanoma microenvironment to augment checkpoint inhibitor immunotherapy. <i>Journal of Clinical Oncology</i> , 2015, 33, 3054-3054.	1.6	2
49	Immune evasion pathways and the design of dendritic cell-based cancer vaccines. <i>Discovery Medicine</i> , 2016, 21, 135-42.	0.5	2
50	A case report of microsatellite instability (MSI)-high, HER2 amplified pancreatic adenocarcinoma with central nervous system metastasis. <i>AME Case Reports</i> , 2021, 5, 14-14.	0.6	1
51	425...Investigation of Wnt ligand signaling regulators as a predictor of Anti-PD-1 response in metastatic melanoma. , 2020, , .		1
52	Identification of a Germline Pyrin Variant in a Metastatic Melanoma Patient With Multiple Spontaneous Regressions and Immune-related Adverse Events. <i>Journal of Immunotherapy</i> , 0, Publish Ahead of Print, .	2.4	1
53	425. Translation of Enhanced Dendritic Cell Vaccines Using a CID-Inducible CD40 Receptor. <i>Molecular Therapy</i> , 2006, 13, S163-S164.	8.2	0
54	Melanoma-derived Wnt5a conditions dendritic cells to promote regulatory T cell differentiation via the upregulation of indoleamine 2,3-dioxygenase: novel pharmacological strategies for augmenting immunotherapy efficacy. , 2014, 2, P209.		0

#	ARTICLE	IF	CITATIONS
55	Role of the type III TGF- β receptor in mediating immunosuppression during breast cancer progression.. Journal of Clinical Oncology, 2010, 28, 10577-10577.	1.6	0
56	Abstract 3548: Loss of the type III TGF- β receptor during cancer progression generates an immunotolerant tumor microenvironment: Translational implications for TGF- β inhibition and immunotherapy biomarker development. , 2012, , .		0
57	Pharmacological Wnt Ligand Inhibition Overcomes Key Tumor-Mediated Resistance Pathways to Anti-PD-1 Immunotherapy. SSRN Electronic Journal, 0, , .	0.4	0